Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Open-source automated insulin delivery shows comparable glycemic outcomes to a commercial hybrid closed-loop system in real-world type 1 pediatric diabetes care: a retrospective cohort study from British Columbia, Canada.

Created on 30 Sep 2026

Authors

Duha Hejla, Kate Hawke, Leah Borovoi, Tom Elliott, Constadina Panagiotopoulos

Published in

Pediatric diabetes. Volume 2026. Pages e009. Epub Sep 08, 2026.

Abstract

Open-source automated insulin delivery shows promise for managing type 1 diabetes, though pediatric efficacy and safety data remain limited. This study aimed to compare real-world glycemic outcomes of open-source automated insulin delivery systems with hybrid closed-loop systems in youth with type 1 diabetes. This retrospective cohort study included individuals aged ≤ 19 years with type 1 diabetes for at least one year who used either open-source automated insulin delivery systems (Loop, iAPS, or AndroidAPS) or hybrid closed-loop systems (Tandem t:slim) for at least six months between January 2015 and June 2024. Data were collected from one month before system initiation to 18 months after initiation or the last clinical visit. Glycated hemoglobin, time in range, and glucose management indicator were evaluated using regression analyses and adjusted linear mixed-effects models. A total of 198 participants (143 open-source automated insulin delivery and 55 hybrid closed-loop users) were included (mean age 13.8 years; 57% male). Over 18 months, glycated hemoglobin decreased from 7.40% to 6.96% in the open-source automated insulin delivery group and from 7.35% to 7.28% in the hybrid closed-loop group. Adjusted analyses showed no significant differences in glucose management indicator or time in range between groups across follow-up. Severe hypoglycemia occurred in one participant per group, and no diabetic ketoacidosis events were observed. Open-source automated insulin delivery systems demonstrated similar long-term glycemic outcomes and safety compared with hybrid closed-loop systems, supporting their use as a safe, non-inferior alternative.

PMID:
42812142
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement